Medtronic Bladder Lawsuit Settlement With Axonics Modulation Technologies 2022

When the medtronic bladder lawsuit is mentioned, there is a curiosity in all of us. Let’s move on to your article to look at this together.

During the recent class action lawsuit, Medtronic received a settlement from Axonics Modulation Technologies, which denies any infringement on seven of the company’s patents. The company has filed seven IPR petitions to contest the validity of the seven Medtronic patents.

Axonics Modulation Technologies filed seven IPR petitions contesting the validity of seven Medtronic patents

Earlier this year, Axonics Modulation Technologies filed seven inter partes review (IPR) petitions to challenge the validity of seven Medtronic bladder patents. The patents in question are related to energy transfer, recharging systems and lead fixation. The USPTO’s Patent Trial and Appeal Board (PTAB) agreed last week that it should review six of these requests for review. The board will announce its findings in the coming months.

Axonics’s patent arsenal is a bit less impressive when compared to Medtronic’s trove of SNM IP. The company recently joined the sacral neuromodulation fray with its rechargeable sacral neuromodulation (r-SNM) system. Medtronic has been in the business for 25 years, releasing a number of pioneering devices. Axonics’s SNM therapy has been proven to reduce symptoms and is now available in hundreds of medical centers in the U.S. and across Europe.

Axonics’s r-SNM system received FDA approval last year. The company also received the CE mark for its rechargeable system last year. In the meantime, Medtronic has been testing the waters with its rechargeable and recharge free sacral neuromodulation systems. The company is hoping to take the lead with its latest offering, a rechargeable system that treats faecal dysfunction and urinary dysfunction.

Despite their patent arsenal, Axonics is only half way through a long patent fight with Medtronic. The two companies have been going at it since last year, when Medtronic first filed charges of patent infringement against the Irvine, California company.

Axonics Modulation Technologies denies patent infringement claims

Earlier this year, Medtronic plc (NYSE: MDT) filed a patent infringement suit against Axonics Modulation Technologies Inc. (NASDAQ: AXON). The suit was filed in the Central District of California. It alleges that Axonics’ r-SNM (Rechargeable Sacral Neuromodulation) System infringes on four Medtronic patents.

The r-SNM System is an implantable, rechargeable SNM system designed to treat urinary retention and fecal incontinence. Axonics’ system is currently approved in the U.S. and Europe. The company has a device that’s been shown to reduce overactive bladder activity in two-thirds of patients. The system also has a 15-year functional life.

Axonics’ device was approved by the FDA in September for the treatment of overactive bladder and fecal incontinence. It’s also expected to be approved for the treatment of urinary retention and fetal incontinence.

The patent infringement lawsuit was filed in November. Axonics’ stock fell 16 percent after the suit was filed. Despite the decline, the company expects its revenue to grow tenfold next year and by 2020.

The patent infringement lawsuit could be a lengthy court battle. Ultimately, a jury would decide whether or not Axonics infringed on a Medtronic patent. If a verdict is rendered, the amount of damages could be staggering.

However, if a settlement is reached, it’s possible that the impact on Medtronic could be far more muted. Axonics could agree to license a patent from Medtronic, but the deal would prevent further erosion of Medtronic’s intellectual property. In exchange, Axonics would likely have to pay ongoing royalties. The licensing agreement would also disincentivize new competitors.

Class action settlement for medtronic bladder lawsuit

Several lawsuits have been filed against Medtronic Inc., a Minneapolis-based company that manufactures medical devices, for their alleged violations of the False Claims Act and the Anti-Kickback Statute.

The lawsuits allege that Medtronic intentionally hid the risks of its products from patients and physicians. Its research was also found to have overstated the benefits of its devices.

Brand Name	INTERSTIM ICON (BLADDER IMPLANT)
Type of Device	INTERSTIM ICON (BLADDER IMPLANT)
Manufacturer (Section D)	MEDTRONIC
MDR Report Key	4251061
MDR Text Key	5110628
Report Number	MW5038995
Device Sequence Number	1
Product Code	EZW
Reporter Country Code	US
Number of Events Reported	1
Summary Report (Y/N)	N
Report Source	Voluntary
Reporter Occupation
Type of Report	Initial
Report Date	10/24/2014
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received	11.06.2014
Is this an Adverse Event Report?	Yes
Is this a Product Problem Report?	Yes
Device Operator
Device Model Number	3037

Patient Treatment Data

Date Received: 11/06/2014 Patient Sequence Number: 1

Treatment

MEDICAL LISTS INCLUDED W/LIST OF MEDS; BABY ASPIRIN

The company was also accused of paying kickbacks to induce neurosurgeons to use Medtronic products. In addition, it was accused of underreporting payments to CMS. It also allegedly paid for more than 100 events at a restaurant owned by Wilson Asfora, who worked for Medtronic.

One of the most recent Medtronic lawsuits involves the company’s Onyx Liquid Embolic System, which is used to block blood flow to vascular malformations. Medtronic’s sales force allegedly persuaded surgeons to use the device outside of its approved uses.

In addition to alleged violations of the False Claims act, Medtronic has been accused of discriminating against a disabled employee. It also fired an employee for taking medical leave because she had a disability.

The company has also been accused of lying to investors about the safety of its devices. HeartWare, which was acquired by Medtronic in 2016, is accused of misrepresenting the safety of its new products to investors.